PRO: Patients With Hepatitis C Virus With Pretreatment Metavir Stage 3 Fibrosis Do Not Require Hepatocellular Carcinoma Surveillance After Sustained Virological Response
Amoah Yeboah‐Korang, Nicole M. Gentile, Claus J. Fimmel – 14 December 2018
Rationing Care: Barriers to Direct‐Acting Antiviral Treatment in Medicaid Treatment Criteria
Phil Waters, Tina Broder – 14 December 2018
Hepatitis C Virus in the Modern Direct‐Acting Antiviral Era: Where Have All the Special Populations Gone?
Christian B. Ramers, Stacey B. Trooskin – 14 December 2018
Entecavir and Peginterferon Alfa‐2a in Adults With Hepatitis B e Antigen–Positive Immune‐Tolerant Chronic Hepatitis B Virus Infection
Jordan J. Feld, Norah A. Terrault, Hsing‐Hua S. Lin, Steven H. Belle, Raymond T. Chung, Naoky Tsai, Mandana Khalili, Robert Perrillo, Stewart L. Cooper, Marc G. Ghany, Harry L.A. Janssen, Anna S. Lok, for the Hepatitis B Research Network – 14 December 2018 – Monotherapy with interferon or nucleoside analog is generally not recommended during the immune‐tolerant (IT) phase of chronic hepatitis B virus (HBV) infection. Recognition that high HBV DNA levels are associated with hepatocellular carcinoma has increased interest in treating HBV in the IT phase.
Sofosbuvir and Ribavirin Eradication of Refractory Hepatitis E in an Immunosuppressed Kidney Transplant Recipient
Mary Drinane, Xiao Jing Wang, Kymberly Watt – 14 December 2018
Impact of Prior Bariatric Surgery on Perioperative Liver Transplant Outcomes
Baris D. Yildiz – 14 December 2018
Recurrence of Hereditary Hemorrhagic Telangiectasia After Liver Transplantation: Clinical Implications and Physiopathological Insights
Jérôme Dumortier, Sophie Dupuis‐Girod, Pierre‐Jean Valette, Alexander Valent, Olivier Guillaud, Jean‐Christophe Saurin, Valérie Hervieu, Philip Robinson, Henri Plauchu, Pierre Paliard, Olivier Boillot, Jean‐Yves Scoazec – 14 December 2018 – Liver transplantation (LT) has been proposed as a curative treatment in hereditary hemorrhagic telangiectasia (HHT) with severe hepatic involvement. We provide a long‐term evaluation of graft status after LT for HHT, with a focus on the risk of recurrence.
Targeting Transforming Growth Factor Beta Signaling in Liver Cancer
Shuyun Rao, Lopa Mishra – 14 December 2018
Combatting Fibrosis: Exosome‐Based Therapies in the Regression of Liver Fibrosis
Li Chen, David A. Brenner, Tatiana Kisseleva – 13 December 2018 – Hepatic fibrosis results from chronic injury and inflammation in the liver and leads to cirrhosis, liver failure, and portal hypertension. Understanding the molecular mechanisms underlying hepatic fibrosis has advanced the prospect of developing therapies for regression of the disease.